Now available!

NEW! "Xarelto®

DVT/PE Starter Pack

Xarelto®: A single-drug, oral option for DVT/PE management now in a convenient package

To prescribe the Starter Pack, simply write:

**First 28 days of Xarelto® treatment included, with easy-to-follow dosing instructions:**
- 15 mg twice daily with food (42 tablets total) for the first 21 days
- 20 mg once daily with food (7 tablets total) for days 22-28

**A single-agent treatment approach from the time of diagnosis**

**Helps to facilitate the dosing transition**

**The only NOAC starter pack available for initiation of DVT/PE treatment**

**Available through retail and outpatient pharmacies**

#1 dispensed NOAC prescribed by Hematologists, Internists and Orthopaedic Surgeons*

*Comparative clinical significance is unknown.

Xarelto® is indicated for the treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE.

For the treatment of VTE, Xarelto® is not recommended as an alternative to unfractionated heparin in patients with acute pulmonary emboli who are haemodynamically unstable, or who may receive thrombolysis or pulmonary embolectomy, since the safety and efficacy of Xarelto® have not been established in these clinical situations.

Xarelto® is not recommended for use in children less than 18 years of age.

Consult the Xarelto® Product Monograph at http://bayer.ca/xarelto for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling 1-800-265-7382.


©Bayer, Bayer Cross, Xarelto and Xarelto Diamond Design are registered trademarks of Bayer AG, used under license by Bayer Inc. All other trademarks are trademarks of their respective owners. ©2015, Bayer Inc.